{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/impetigo/diagnosis/clinical-features/","result":{"pageContext":{"chapter":{"id":"8dee3a55-eaa2-5aab-b6e5-9a89ad394715","slug":"clinical-features","fullItemName":"Clinical features","depth":2,"htmlHeader":"<!-- begin field 8a7b7f9f-b9c5-4386-909f-a95f00ec3e97 --><h2>What are the clinical features?</h2><!-- end field 8a7b7f9f-b9c5-4386-909f-a95f00ec3e97 -->","summary":"","htmlStringContent":"<!-- begin item 3d642976-2a1f-4cd7-9bba-a95f00ec3e01 --><!-- begin field d4f1b2f1-f8c0-43aa-b063-a95f00ec3e97 --><ul><li><strong>Non-bullous impetigo</strong><ul><li>Lesions begin as thin walled vesicles or pustules (seldom seen on clinical examination as they rupture quickly) which release exudate forming a characteristic golden/brown crust. Once crusts have dried they separate leaving mild erythema which then fades — healing occurs spontaneously without scarring within 2-3 weeks.<ul><li>The course may be more prolonged in people with pre-existing skin conditions (such as eczema or scabies) or in hot/humid climates.</li></ul></li><li>Lesions can develop anywhere on the body but are most common on exposed skin on the face (in particular the peri-oral and peri-nasal areas), limbs and flexures (such as the axillae). Satellite lesions may develop following autoinoculation.</li><li>Non-bullous impetigo is usually asymptomatic but may be mildly itchy.</li><li>Systemic features are uncommon but in severe cases regional lymphadenopathy and fever may occur.</li></ul></li><li><strong>Bullous impetigo</strong><ul><li>Lesions appear as flaccid fluid filled vesicles and blisters (often with a diameter of 1-2cm) which can persist for 2-3 days. Blisters rupture leaving a thin flat yellow/brown crust. Healing usually occurs within 2-3 weeks without scarring.</li><li>Lesions can occur anywhere on the body but are most common on the flexures, face, trunk and limbs.<ul><li>Bullous impetigo may be particularly widespread in infants.</li></ul></li><li>Systemic features may occur if large areas of skin are affected and include fever, lymphadenopathy, diarrhoea and weakness.</li></ul></li></ul><!-- end field d4f1b2f1-f8c0-43aa-b063-a95f00ec3e97 --><!-- end item 3d642976-2a1f-4cd7-9bba-a95f00ec3e01 -->","topic":{"id":"df142ae3-a675-5faa-955f-deba3aa176bc","topicId":"08c2a82c-2e88-477a-a00d-e75b47770e61","topicName":"Impetigo","slug":"impetigo","lastRevised":"Last revised in February 2020","chapters":[{"id":"5d5b7bff-ba78-5008-89df-49963bc208b7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"35862574-df78-5554-bbe6-86275287ef3a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc13ef99-c08d-5361-89de-765433a18ce3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8abd7c1c-e4d5-5fc6-9deb-2cfbbee04b6a","slug":"changes","fullItemName":"Changes"},{"id":"5105f48d-40d4-5c74-bec6-af0574471e5a","slug":"update","fullItemName":"Update"}]},{"id":"8c2bfe64-9ced-531b-b641-00b4ff18bd7c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"eaefc2a4-19e1-525e-82f4-dccc7115b2b6","slug":"goals","fullItemName":"Goals"},{"id":"5a84c42b-0cca-52ed-9924-c54417494c01","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5275b616-56f0-5b49-b2df-0cbffee7e3fc","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6ed2c217-68c2-5ecc-8c61-7187fcbead1b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1dec750c-6e33-5adf-ae33-87a7f4a042c2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"abff03ac-c7cc-5fe7-b6de-0871e4a2846a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba37e0a2-65cd-52ec-8992-3299b96c1ea0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9440ce15-e09d-57c4-9ff1-70e323defaf3","slug":"definition","fullItemName":"Definition"},{"id":"605ba802-106d-5b36-93df-7644ebd9231d","slug":"causes","fullItemName":"Causes"},{"id":"863740f1-ab66-5109-bcb1-30ef774d0d2c","slug":"incidence","fullItemName":"Incidence"},{"id":"69d86930-4301-54ce-8d47-133d348f0b7b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"afe26e4f-1499-57be-a412-9d17510303e9","slug":"complications","fullItemName":"Complications"}]},{"id":"cf492669-e436-53c8-b2b7-f369198b6622","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8dee3a55-eaa2-5aab-b6e5-9a89ad394715","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"46b7f694-9523-5232-ad5d-ca6d1dba2c94","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6e579521-48f9-59b3-a8e3-5e8e37473653","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eebe4528-d9d4-5e2e-ab08-fe1255e1564b","fullItemName":"Management","slug":"management","subChapters":[{"id":"3f2b5528-3a31-51ee-9a7c-713b86cf2854","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"60f683cb-4447-5ecd-9b90-245b33e20336","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f5f53214-ec8d-5ca7-8dde-0ef07d26b140","slug":"hydrogen-peroxide","fullItemName":"Hydrogen peroxide"},{"id":"178eb388-927e-59ea-8289-59bd71cf7ae0","slug":"fusidic-acid","fullItemName":"Fusidic acid"},{"id":"7ee4e706-9719-555b-85eb-18477604621b","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"58ff6676-3c7d-5610-98c3-5e6b6b326c5c","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"9983753e-f306-528c-bcad-5c5e37e49831","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4825af9d-eb38-5c45-a29d-40a17e11e044","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"484c3649-34b0-537b-9431-0907ac172480","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e05d1269-8a31-569f-b89a-f9609763db8b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c7093c62-22f3-531b-ab5c-3c222fd9220e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25fc1ec7-3a38-5636-9e71-37951cbae3e8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f7eec7c7-f55f-53ec-afb1-6fa00707cb90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9e2f110a-ec9f-5728-8f52-cb51f2bfe209","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cf492669-e436-53c8-b2b7-f369198b6622","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"84fbe6cd-d49d-51ac-998a-635325fe1e94","slug":"basis-for-recommendation-1ed","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 777f90b7-70d1-431f-a16a-a95f00ec6705 --><h3>Basis for recommendation</h3><!-- end field 777f90b7-70d1-431f-a16a-a95f00ec6705 -->","summary":null,"htmlStringContent":"<!-- begin item 1ed9f92e-2bad-440f-a321-a95f00ec6692 --><!-- begin field fdef487a-197d-45cd-af78-a95f00ec6705 --><p>The information on the clinical features of impetigo is based on the clinical guidelines <em>Impetigo </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">PCDS, 2018</a>] and <em>Health protection in schools and other childcare facilities. A practical guide for staff on managing cases of infectious diseases in schools and other childcare settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">PHE, 2018</a>], the Canadian clinical effectiveness review <em>Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">CADTH, 2017</a>], Rooks textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Hay, 2016</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Hartman-Adams, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">Allmon, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/impetigo/references/\">BMJ Best Practice, 2018</a>].</p><!-- end field fdef487a-197d-45cd-af78-a95f00ec6705 --><!-- end item 1ed9f92e-2bad-440f-a321-a95f00ec6692 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}